NASDAQ : DWTX

Dogwood Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.28 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 43.51M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.

Details

NameDogwood Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees8
Founded2012
CeoGregory Duncan
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS92829J2033
Cusip92829J203
Cik0001818844
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Gregory DuncanChairman and Chief Executive Officer
Angela WalshChief Financial Officer, Secretary and Treasurer
Dr. R. Michael Gendreau M.D., Ph.D.Chief Medical Officer
Dr. William L. Pridgen M.D.Founder and Member of Scientific Advisory Board
Ralph D. Grosswald M.P.H.Senior Vice President of Operations
Carol Duffy Ph.D.Chief Scientific Advisor

Contact

Address44 Milton Avenue, Alpharetta, Georgia 30009, United States
Phone866 620 8655
Websitehttps://dwtx.com